Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMNP
CUSIPN/A
Phone201-464-2677
Debt
Debt-to-Equity Ratio0.15
Current Ratio0.31
Quick Ratio0.31
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book0.31
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-17,880,000.00
Net MarginsN/A
Return on Equity-248.29%
Return on Assets-59.87%
Miscellaneous
Employees7
Outstanding Shares32,000,000
Market Cap$6.87
Immune Pharmaceuticals (NASDAQ:IMNP) Frequently Asked Questions
What is Immune Pharmaceuticals' stock symbol?
Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."
How were Immune Pharmaceuticals' earnings last quarter?
Immune Pharmaceuticals Inc (NASDAQ:IMNP) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.05. View Immune Pharmaceuticals' Earnings History.
When is Immune Pharmaceuticals' next earnings date?
What price target have analysts set for IMNP?
1 Wall Street analysts have issued 12-month price targets for Immune Pharmaceuticals' stock. Their predictions range from $2.00 to $2.00. On average, they expect Immune Pharmaceuticals' share price to reach $2.00 in the next year. This suggests a possible upside of 900.0% from the stock's current price. View Analyst Ratings for Immune Pharmaceuticals.
What is the consensus analysts' recommendation for Immune Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immune Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Immune Pharmaceuticals' key competitors?
Some companies that are related to Immune Pharmaceuticals include Sernova (SEOVF), Akari Therapeutics (AKTX), Provectus Biopharmaceuticals (PVCT), KITOV PHARMA LT/S (KTOV), X T L Biopharmaceuticals (XTLB), RegeneRx Biopharmaceuticals (RGRX), Catabasis Pharmaceuticals (CATB), Diffusion Pharmaceuticals (DFFN), Nuvo Pharmaceuticals (NRIFF), Eyegate Pharmaceuticals (EYEG), ESSA Pharma (EPIX), Midatech Pharma (MTP), Pulmatrix (PULM), IntelliPharmaCeutics Intl (IPCI) and Egalet (EGLT).
Who are Immune Pharmaceuticals' key executives?
Immune Pharmaceuticals' management team includes the folowing people:
- Dr. Elliot M. Maza CPA, J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 62)
- Dr. Anthony S. Fiorino, COO & Chief Medical Officer (Age 51)
- Mr. Christine J. Petraglia, Director of Investor Relations
- Ms. Anna Baran-Djokovic J.D., Director of Corp. Affairs
- Dr. Miri Ben-Ami, Pres of Immune Oncology Pharmaceuticals Inc
Has Immune Pharmaceuticals been receiving favorable news coverage?
News coverage about IMNP stock has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a daily sentiment score of 0.11 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 44.72 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Immune Pharmaceuticals?
Shares of IMNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immune Pharmaceuticals' stock price today?
One share of IMNP stock can currently be purchased for approximately $0.20.
How big of a company is Immune Pharmaceuticals?
Immune Pharmaceuticals has a market capitalization of $6.87 million. Immune Pharmaceuticals employs 7 workers across the globe.
How can I contact Immune Pharmaceuticals?
Immune Pharmaceuticals' mailing address is 550 Sylvan Avenue, Englewood Cliffs NJ, 07632. The biopharmaceutical company can be reached via phone at 201-464-2677 or via email at [email protected]
MarketBeat Community Rating for Immune Pharmaceuticals (NASDAQ IMNP)
MarketBeat's community ratings are surveys of what our community members think about Immune Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
